Immunomedics, UCB Launch Epratuzumab SLE Phase III
By Tom Wall
Wednesday, December 15, 2010
Partners Immunomedics Inc. and UCB SA have launched two Phase III studies of epratuzumab in patients with moderate to severe systemic lupus erythematosus (SLE), the most common form of lupus, a chronic and potentially fatal autoimmune disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.